Dawn Christine Maroney Sells 113,319 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) President Dawn Christine Maroney sold 113,319 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $20.01, for a total value of $2,267,513.19. Following the completion of the transaction, the president directly owned 1,667,237 shares in the company, valued at $33,361,412.37. The trade was a 6.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Dawn Christine Maroney also recently made the following trade(s):

• On Friday, December 12th, Dawn Christine Maroney sold 16,681 shares of Alignment Healthcare stock. The stock was sold at an average price of $20.02, for a total transaction of $333,953.62.

Alignment Healthcare Stock Performance

Alignment Healthcare stock traded up $0.75 during mid-day trading on Monday, reaching $20.11. 3,366,998 shares of the stock traded hands, compared to its average volume of 3,039,179. Alignment Healthcare, Inc. has a 12-month low of $10.18 and a 12-month high of $21.06. The company has a debt-to-equity ratio of 1.99, a current ratio of 1.61 and a quick ratio of 1.61. The business’s 50-day moving average is $17.65 and its 200-day moving average is $15.84. The stock has a market capitalization of $4.02 billion, a PE ratio of -167.58 and a beta of 1.16.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Thursday, October 30th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.03. Alignment Healthcare had a negative return on equity of 16.23% and a negative net margin of 0.57%.The company had revenue of $993.70 million during the quarter, compared to analysts’ expectations of $980.90 million. During the same quarter last year, the firm earned ($0.14) earnings per share. The firm’s quarterly revenue was up 43.5% compared to the same quarter last year. As a group, sell-side analysts predict that Alignment Healthcare, Inc. will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Alignment Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Alignment Healthcare by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 13,968,584 shares of the company’s stock worth $243,752,000 after buying an additional 664,769 shares during the period. Wellington Management Group LLP grew its position in Alignment Healthcare by 167.3% during the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after buying an additional 6,940,277 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its position in Alignment Healthcare by 5.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 9,078,113 shares of the company’s stock valued at $169,035,000 after acquiring an additional 429,071 shares in the last quarter. Hood River Capital Management LLC grew its position in shares of Alignment Healthcare by 6.0% during the 2nd quarter. Hood River Capital Management LLC now owns 5,517,336 shares of the company’s stock valued at $77,243,000 after acquiring an additional 311,424 shares during the period. Finally, 8 Knots Management LLC lifted its stake in Alignment Healthcare by 6.4% in the second quarter. 8 Knots Management LLC now owns 5,015,881 shares of the company’s stock worth $70,222,000 after purchasing an additional 300,409 shares during the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, October 8th. JPMorgan Chase & Co. raised shares of Alignment Healthcare from a “neutral” rating to an “overweight” rating and raised their price target for the company from $18.00 to $20.00 in a research report on Monday, November 24th. Barclays lifted their price target on Alignment Healthcare from $13.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, October 31st. Zacks Research lowered shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. Finally, KeyCorp reissued an “overweight” rating on shares of Alignment Healthcare in a research report on Monday, November 24th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Alignment Healthcare has a consensus rating of “Moderate Buy” and an average price target of $20.05.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.